BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, December 27, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

April 5, 2000

View Archived Issues

Array BioPharma and Lilly form drug discovery collaboration

Read More

CollaGenex seeks FDA approval for new dosage form of Periostat

Read More

Karo Bio to acquire Novalon

Read More

Significant progress reported by Genzyme Molecular Oncology for 1999

Read More

Aventis launches Arava in Canada for treatment of rheumatoid arthritis

Read More

First phase II clinical trial of ABX-IL-8 begins in psoriasis

Read More

New phosphoglycolipid useful for protecting against cardiac ischemia-reperfusion damage

Read More

Chemokine receptor modulators in early development at AstraZeneca

Read More

Helsinn initiates phase III testing of in-licensed antiemetic

Read More

Carboxylic acid PPAR modulators presented by Ono

Read More

Merck's new GABA-A receptor modulators particularly useful for Alzheimer's disease

Read More

Scios compounds useful for conditions characterized by excess p38alpha or TGF-beta activity

Read More

Merck describes preparation and use of new anticoagulants

Read More

Uprima to be considered for ED next week by FDA advisory committee

Read More

Another indication for Enbrel will be discussed at advisory committee meeting

Read More

Novel tubulin-binding antimitotic agent characterized in vitro by Abbott scientists

Read More

Celgene's IMiDs and thalidomide show activity as COX-2 inhibitors

Read More

WP-769: a doxorubicin analogue that combines oral activity and enhanced effect against topo II

Read More

Promising flavonoid discovered by Dutch investigators for preventing doxorubicin cardiotoxicity

Read More

Ro-31-7453: extensive preclinical and early clinical data presented this week to the AACR

Read More

DuPont licenses two cardiac compounds from Adenosine Therapeutics

Read More

Clinical study suggests SuperGen's Nipent effective in treating GVHD

Read More

FDA gives go-ahead for Access to commence OraDisc clinical trials

Read More

Matrix files initial section of IntraDose NDA with FDA

Read More

German researchers provide data supporting therapy with S-4718 + ciclosporin in cardiac transplants

Read More

Efficacy and mechanism of action of FR-167653 in protecting against lung I/R injury

Read More

Newly formed company to market TOBI in the Dutch market

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing